Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 238,226,771 papers from all fields of science
Search
Sign In
Create Free Account
LCZ 696
Known as:
LCZ-696
, LCZ696
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
6 relations
Broader (3)
Aminobutyrates
Angiotensin Receptor Antagonists
Tetrazoles
Narrower (3)
Entresto
sacubitril
sacubitril / valsartan
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Duální inhibice AT1 receptoru pro angiotenzin II a neprilysinu nebo inhibice angiotenzin konvertujícího enzymu
J. Špinar
,
L. Špinarová
,
J. Vítovec
2018
Corpus ID: 133417429
Dualni antagonista receptorů AT1 pro angiotenzin II a neprilysinu s generickým nazvem sacubitril-valsartan (dřive LZC696 nebo…
Expand
2018
2018
Nový duální inhibitor AT1 receptorů a vazopeptidáz (LCZ 696) a studie PARADIGM HF
J. Špinar
,
J. Vítovec
,
L. Špinarová
2018
Corpus ID: 198295829
Nový dualni antagonista receptorů pro angiotenzin II (ARB) a neprilysinu (NEP) je dnes již schvalen a registrovan pro lecbu…
Expand
2016
2016
LCZ696 przełomem w leczeniu przewlekłej niewydolności serca z obniżoną frakcją wyrzutową lewej komory
S. Sobczak
,
M. Lelonek
2016
Corpus ID: 76471776
Niewydolnośc serca jest czestym problemem klinicznym; w krajach uprzemyslowionych wystepuje u 1–2% doroslej populacji. Mimo…
Expand
Review
2016
Review
2016
LCZ696, an Angiotensin–neprilysin Inhibitor Versus Enalapril in Heart Failure – Summary of PARADIGM-HF Results
J. Cardoso
2016
Corpus ID: 77186074
Disclosure: José Silva Cardoso has consulted and received speaker fees and investigational grants from Novartis. He was the…
Expand
2016
2016
Sacubitril-valsartan (LCZ696) v léčbě srdečního selhání
J. Vítovec
,
L. Špinarová
,
J. Špinar
2016
Corpus ID: 79373515
Nový dualni antagonista receptorů pro angiotenzin II (ARB) a neprilysinu s generickým nazvem sacubitril-valsartan (dřive LZC 696…
Expand
2016
2016
Paramount Importance of Angiotensin Receptor Neprilysin Inhibitor in Heart Failure Management.
Hilman Zulkifli Amin
,
Lukman Zulkifli Amin
,
Firman Zulkifli Amin
Acta Medica Iranica
2016
Corpus ID: 13715517
2015
2015
ПЕРВЫЙ ОПЫТ КЛИНИЧЕСКОГО ПРИМЕНЕНИЯ ДВОЙНОГО ИНГИБИТОРА АНГИОТЕНЗИНОВЫХ РЕЦЕПТОРОВ И НЕПРИЛИЗИНА LCZ696 У БОЛЬНЫХ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ СО СНИЖЕННОЙ ФРАКЦИЕЙ ВЫБРОСА
Жанна Давидовна Кобалава
,
Е. П. Павликова
,
+5 authors
В. С. Моисеев
2015
Corpus ID: 185477156
2015
2015
Abstract 17955: Reduction in 30-day Rehospitalization After Discharge From a Heart Failure Admission in Patients Receiving LCZ696 versus Enalapril: PARADIGM-HF
S. Solomon
,
M. Packer
,
+6 authors
J. McMurray
2015
Corpus ID: 81721887
Introduction: The angiotensin receptor neprilysin inhibitor LCZ696 reduced cardiovascular death, heart failure hospitalization…
Expand
2011
2011
Natriuretic peptide inhibition in the presence of angioten-sin receptor blockade following short-term treatment with LCZ 696 in heart failure patients: effect on ANP, BNP, NT-proBNP and cGMP
Z. Kobalava
,
O. Averkov
,
+6 authors
E. Pavlikova
2011
Corpus ID: 78672798
2010
2010
Abstract 19378: First Experience with Concomitant AT1 and Neprilysin (NEP 24.11) Inhibition with LCZ696 in Patients with Chronic Heart Failure
Z. Kobalava
,
E. Pavlikova
,
+5 authors
P. Jordaan
2010
Corpus ID: 57434174
Introduction: In the setting of heart failure (HF), chronic RAAS activation is detrimental, while NEP (neprilysin, NEP 24.11…
Expand